Canada's AbCellera Q3 revenue beats analyst estimates
ABCL•AbCellera reported third-quarter revenue of $10.6 million, above the $8.42 million analyst estimate. Its net loss narrowed to $40.8 million from $57.1 million a year earlier, and liquidity rose to more than $890 million after a $200 million capital raise.
1. Revenue and loss
AbCellera's third-quarter revenue was $10.6 million, beating the $8.42 million analyst estimate. The company reported a loss per share of $0.13 and a net loss of $40.8 million, compared with a $57.1 million net loss a year earlier. Lower research and development and selling, general and administrative expenses contributed to the narrower loss.
2. Pipeline and outlook
AbCellera cited positive top-line Phase 2 results for ABCL635 and Phase 1 results for ABCL575 as key quarterly milestones. Three programs—ABCL992, ABCL385 and ABCL646—advanced to IND-enabling activities. The company expects to initiate late-stage development of ABCL635 for menopausal vasomotor symptoms in 2027 and plans trials for breast and prostate cancer-related vasomotor symptoms that year.
